Abstracts tagged "Cost-Effectiveness"

Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Brandon Blau¹, Kelsey Gripp¹, Catherine MacLean² and Bella Mehta², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
Abstract Number: 0274 • ACR Convergence 2024
Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Yana Pryymachenko¹, Ross Wilson¹, Haxby Abbott¹, Nicola Dalbeth² and Lisa Stamp³, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Sama Hajizadeh¹, Tyson Barrett², Yue Yin³ and Dr Tarun Sharma⁴, ¹Allegheny Health Network, Pittsburgh, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, ⁴West Penn Hospital, Pittsburgh, PA
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
Abstract Number: 0553 • ACR Convergence 2024
Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
Sanjeev Shrestha¹, Angela Bobak², Idorenyin Udoeyo³, Pradeep Puri⁴, Jordan Law⁵ and David Bulbin⁶, ¹Geisinger Medical Center, Bloomsburg, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Danville, ⁵Geisinger Health System, Danville, ⁶Geisinger Health System, Danville, PA
Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
Abstract Number: 1046 • ACR Convergence 2024
Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
Abstract Number: 1050 • ACR Convergence 2024
The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Daniel Betensky¹, Jeffrey Katz¹, Catherine Yang², David Hunter³, Jamie Collins¹, Candace Feldman¹, Karen Smith¹, Stephen Messier⁴, Jason Kim⁵, Faith Selzer⁶ and Elena Losina¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁴Wake Forest University, Winston Salem, NC, ⁵Arthritis Foundation, Atlanta, GA, ⁶Brigham and Women's Hospital, Amesbury, MA
Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
Abstract Number: 1116 • ACR Convergence 2024
Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry
Shivang Chaudhary¹, Kaushik Gokul¹, Kishan Patel², Simran Bhimani³, Yash Deshpande³, Adam Kilian¹, Ravi Nayak¹, Deana Mikhalkova¹ and Chaitanya Rojulpote¹, ¹Saint Louis University, St. Louis, MO, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA
Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
Abstract Number: 1742 • ACR Convergence 2024
Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care
Marina Latif¹, Kyla Driest², Erin Frank³, Allayne Stephans³, Stacey Tarvin⁴ and Angela Robinson⁵, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rainbow Babies and Children's Hospital, Cleveland, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Excessive healthcare spending in the United States remains a growing concern, and teaching high-value care is essential to combat wasted costs. It is…
Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Barbara Bayeh¹, Fanny Neira¹, Karina Bonfiglioli¹, Nadia Aikawa², ANA PAULA ASSAD¹, Renata Miossi¹, Fernando Souza³, Carlos Emilio Insfran Echauri¹, Henrique Giardini¹, Emily Figueiredo Neves Yuki¹, Henrique Carriço Da Silva¹, Andre Franco¹, Diogo Domiciano¹, Julio Moraes⁴, Eloisa Bonfa¹, Carla Goncalves Schahin Saad³, Ana Cristina Medeiros-Ribeiro⁵ and Andrea Shimabuco³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
Abstract Number: 1001 • ACR Convergence 2023
Distance Not Travelled in a Tele-Rheumatology Shared Care Model: Leveraging the Expertise of an Advanced Clinician Practitioner in Arthritis Care (ACPAC)-trained Extended Role Practitioner (ERP) in Rural-remote Ontario
Amanda Steiman¹, Jocelyne Murdoch², Rachel Shupak³, Taucha Inrig⁴ and Katie Lundon⁵, ¹Sinai Health System, Toronto, ON, Canada, ²Arthritis Society, Toronto, ON, Canada, ³St. Michael's Hospital/University of Toronto, Toronto, ON, Canada, ⁴St. Michael's Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: A shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…
Abstract Number: 1840 • ACR Convergence 2023
Value of Various Intra-Articular Injections for Knee Osteoarthritis Management
Hanna Mass¹, Jamie Collins¹, david Hunter², Catherine Yang¹, Morgan Jones¹, Stephen Messier³, Tuhina Neogi⁴, A. David Paltiel⁵, Jeffrey Katz¹ and Elena Losina⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³Wake Forest University, Winston-Salem, NC, ⁴Boston University School of Medicine, Boston, MA, ⁵Yale School of Public health, New Haven, CT, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].